SCHEMBL17849758

SCHEMBL17849758

S=c1cc(-c2ccnc(Cl)c2)ss1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.46
HDAC4 P56524 3/20 0.46
HDAC1 Q13547 3/20 0.46
HDAC7 Q8WUI4 3/20 0.46
HDAC2 Q92769 3/20 0.46
HDAC10 Q969S8 3/20 0.46
HDAC11 Q96DB2 3/20 0.46
HDAC8 Q9BY41 3/20 0.46
HDAC6 Q9UBN7 3/20 0.46
HDAC9 Q9UKV0 3/20 0.46
HDAC5 Q9UQL6 3/20 0.46
ADORA2A P29274 2/20 0.42
ADORA1 P30542 2/20 0.42
MEN1 O00255 1/20 0.42
PGR P06401 1/20 0.42
ADRB2 P07550 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
MAOA P21397 1/20 0.42
TBXA2R P21731 1/20 0.42
SLC6A2 P23975 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17849753 0.75 HDAC8 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4027001 0.73 IDO1 (0.55) ADORA2AADORA1IDO1CYP19A1CCNC
SCHEMBL17849757 0.71 HDAC3 (0.38) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9534281 0.71 HDAC3 (0.64) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3169941 0.69 IDO1 (0.45) ADORA2AADORA1IDO1CYP19A1CCNC
SCHEMBL1681410 0.69 CYP2E1 (0.47) KCNH2IDO1CYP19A1S1PR1S1PR3
SCHEMBL1681489 0.68 HSD17B1 (0.46) ADORA2AADORA1IDO1CYP19A1CCNC
SCHEMBL17632269 0.67 DYRK1A (0.54) ADORA2AADORA1MEN1KMT2AIDO1
SCHEMBL18775606 0.67 PARP10 (0.40) PGRIDO1CYP19A1CCNCCDK8
SCHEMBL23348686 0.66 IDO1 (0.53) ADORA2AADORA1IDO1CYP19A1CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9370504-B2 Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-α SNU R&DB FOUNDATION (KR) 2016-06-21 US disclosed